These names combine healthcare research with state-of-the art technology.
A handful of deals have been announced this week alone and they give rise to expectations of more acquisitions to come.
Also, interpreting Tuesday's market, Covid-19 vaccine update, and manufacturing growth.
Centene is a $110 billion in revenue company you've probably never heard of. Here's how to play it.
Plus, Veeva Systems reports stellar results and ups its guidance.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Shares of the industrial and technology giant have been listless for quite a while but finally appear poised for a rally.
Do your fundamental homework and consider going long FLDM.
Getting dropped from the Dow may give PFE the catalyst it needs to make a big move one way or the other.
Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.